Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features
Open Access
- 2 September 2014
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (19) , 9295-9307
Abstract
Treatment resistance significantly inhibits the efficiency of targeted cancer therapies in drug-sensitive genotypes. In the current work, we studied mechanisms for rapidly occurring, adaptive resistance in targeted therapy-sensitive lung, breast, and melanoma cancer cell lines. The results show that in ALK translocated lung cancer lines H3122 and H2228, cells with cancer stem-like cell features characterized by high expression of cancer stem cell markers and/or in vivo tumorigenesis can mediate adaptive resistance to oncogene ablative therapy. When pharmacological ablation of ALK oncogene was accompanied with PI3K inhibitor or salinomycin therapy, cancer stem-like cell features were reversed which was accompanied with decreased colony formation. Furthermore, co-targeting was able to block the formation of acquired resistance in H3122 line. The results suggest that cells with cancer stem-like cell features can mediate adaptive resistance to targeted therapies. Since these cells follow the stochastic model, concurrent therapy with an oncogene ablating agent and a stem-like cell-targeting drug is needed for maximal therapeutic efficiency.Keywords
This publication has 30 references indexed in Scilit:
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresProceedings of the National Academy of Sciences, 2009
- Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput ScreeningCell, 2009
- Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon TumorigenesisCancer Research, 2009
- The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populationsProceedings of the National Academy of Sciences, 2009
- Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal TransitionPLOS ONE, 2008
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- Molecular Definition of Breast Tumor HeterogeneityCancer Cell, 2007
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006